Literature DB >> 2171169

Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir.

D Eisenmann1, H Knipp, H Laube, T Stegmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2171169

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

2.  Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.

Authors:  J M Aguado; M A Gomez-Sanchez; C Lumbreras; J Delgado; M Lizasoain; J R Otero; J J Rufilanchas; A R Noriega
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 3.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 4.  Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Markus J Barten; Fausto Baldanti; Alexander Staus; Christian M Hüber; Kyriaki Glynou; Andreas Zuckermann
Journal:  Life (Basel)       Date:  2022-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.